This article is more than 5 years old. Information may no longer be current.
Patients with metastatic RCC who developed hypothyroidism experienced longer PFS
Click Here to Manage Email Alerts
Patients with metastatic renal cell carcinoma who developed hypothyroidism after treatment with sunitinib or sorafenib experienced longer PFS, according to study results.
The researchers aimed to investigate how hypothyroidism develops in patients with metastatic renal cell carcinoma who have been treated with sunitinib (Sutent, CPPI CV) and sorafenib (Nexavar, Bayer Healthcare), and how hypothyroidism affects PFS.
The retrospective chart review involved patients treated with these two drugs from 2005 to 2010.
Researchers included data from 73 treatment periods in the final analysis.
Hypothyroidism occurred in 15 of 34 (44%) patients treated with sunitinib and six of 22 (27%) patients treated with sorafenib.
The hazard ratio for development of hypothyroidism with sorafenib vs. sunitinib was significant (HR=0.38; 95% CI, 0.14-0.97), study results showed.
Patients who developed hypothyroidism during treatment had a PFS of 18.2 months compared with 10.1 months for treated patients who did not develop hypothyroidism (P=.01).
“This study demonstrated a significant difference in the incidence of hypothyroidism during treatment with sunitinib and sorafenib, with a higher incidence of hypothyroidism in patients treated with sunitinib,” the researchers concluded. “The development of hypothyroidism was associated with a longer progression-free survival.”
Click Here to Manage Email Alerts